Effect of zinc supplementation on serum levels of nerve growth factor in the treatment of diabetic retinopathy
Phase 2
- Conditions
- Diabetic retinopathy.Diabetic retinopathyH36.0*
- Registration Number
- IRCT2014042117150N2
- Lead Sponsor
- Vice chancellor for Research, Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
age range 40-70 years old; suffering from type 2 diabetes; subject diagnosed with diabetic retinopathy based on ETDRS and the DRS criteria.
Exclusion criteria: insulin injection; hving chronic diseases such as cardiovascular disorders, renal and hepatic,asthma and allergy; having malabsorption syndrome and inflammatory bowel disease; pregnancy and lactation; drugs interfering with zinc (Penicillin amine, Diethylenetriamine pentaacetate); receiving nutritional supplements from 2 months before the study (zinc, calcium, vitamin A and iron); exercise on a regular basis; having a mental illness such as depression; infectious diseases and AIDS; alcoholism.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum concentration of zinc. Timepoint: At baseline and after 3 months of intervention. Method of measurement: Atomic absorption spectrophotometry.;Serum concentration of nerve growth factor. Timepoint: At baseline and after 3 months of intervention. Method of measurement: ELISA.
- Secondary Outcome Measures
Name Time Method Insulin Resistance Index. Timepoint: At baseline and after 8 weeks of intervention. Method of measurement: HOMA-IR.;Systolic blood pressure. Timepoint: At baseline and after 8 weeks of intervention. Method of measurement: Stethoscope and sphygmomanometer.;Diastolic blood pressure. Timepoint: At baseline and after 8 weeks of intervention. Method of measurement: Sphygmomanometer.